^
Association details:
| Biomarker: | ATM mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
Published date:
05/16/2018
Excerpt:
Cohorts 1 (C1) and 2 (C2) enrolled patients (pts) with RECIST-measurable PD-L1+ and PD-L1– disease, respectively….The response rate was numerically higher in pts with somatic BRCA1/2 or ATM mutations (12%)….Pembro shows antitumor activity and disease control with acceptable safety in pts with docetaxel-refractory mCRPC, regardless of PD-L1 status...
DOI:
10.1200/JCO.2018.36.15_suppl.5007
Trial ID:
